Published in CMAJ on October 19, 2009
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int (2010) 1.46
Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol (2011) 1.04
Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int (2011) 0.95
An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures. J Bone Miner Res (2013) 0.82
Probiotics (Bifidobacterium longum) Increase Bone Mass Density and Upregulate Sparc and Bmp-2 Genes in Rats with Bone Loss Resulting from Ovariectomy. Biomed Res Int (2015) 0.81
Use of oral bisphosphonates by older adults with fractures and impaired renal function. Can J Hosp Pharm (2011) 0.77
Seven day insertion rest in whole body vibration improves multi-level bone quality in tail suspension rats. PLoS One (2014) 0.77
Atypical femoral fractures. CMAJ (2010) 0.75
Vitamin D deficiency. N Engl J Med (2007) 59.34
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
The diagnosis of osteoporosis. J Bone Miner Res (1994) 10.90
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet (2007) 9.61
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med (2007) 7.38
Interventions for preventing falls in elderly people. Cochrane Database Syst Rev (2003) 7.05
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Effect of Vitamin D on falls: a meta-analysis. JAMA (2004) 6.64
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med (2006) 6.14
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res (1997) 5.69
Osteoporosis. Lancet (2006) 5.40
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
Risk of subsequent fracture after low-trauma fracture in men and women. JAMA (2007) 4.19
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Concern Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA (2007) 3.63
Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess (Full Rep) (2007) 3.51
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 3.45
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med (2000) 3.16
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev (2005) 3.07
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int (2008) 2.74
Vitamin D insufficiency in a population of healthy western Canadians. CMAJ (2002) 2.73
Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med (2008) 2.66
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev (2002) 2.49
Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ (2006) 2.35
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32
The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int (2006) 2.24
Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J (2005) 2.15
Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab (2007) 2.11
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 2.00
Alendronate and atrial fibrillation. N Engl J Med (2007) 2.00
Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc (2004) 1.84
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 1.74
Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int (2008) 1.68
A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab (2008) 1.66
Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv (2008) 1.61
Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ (2008) 1.54
Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev (2002) 1.53
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int (2004) 1.48
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 1.46
Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev (2002) 1.44
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess (2005) 1.42
Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev (2002) 1.34
Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int (2004) 1.29
Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med (2007) 1.29
Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord (2005) 1.27
The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. QJM (2007) 1.21
Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom (2008) 1.20
Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom (2007) 1.15
Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys (2008) 1.12
Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis. J Clin Epidemiol (2006) 1.09
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int (2005) 1.09
Validation of ten-year fracture risk prediction: a clinical cohort study from the Manitoba Bone Density Program. Bone (2008) 1.07
Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev (2002) 1.02
Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res (2006) 1.01
Geographic variation of bone mineral density and selected risk factors for prediction of incident fracture among Canadians 50 and older. Bone (2008) 1.00
Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int (2004) 1.00
Assessing response to osteoporosis therapy. Osteoporos Int (2008) 0.95
The Harstad injury prevention study: the characteristics and distribution of fractures amongst elders--an eight year study. Int J Circumpolar Health (1999) 0.92
Clinical utility of laboratory testing in women with osteoporosis. Osteoporos Int (2004) 0.89
Effect of combined exercise training on bone, body balance, and gait ability: a randomized controlled study in community-dwelling elderly women. J Bone Miner Metab (2008) 0.87
Nonpharmacological approaches to improve bone health and reduce osteoporosis. Curr Opin Rheumatol (2008) 0.85
The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. Semin Arthritis Rheum (2006) 0.82
Could a policy of provision of hip protectors to elderly nursing home residents result in cost savings in acute hip fracture care? The case of Ontario, Canada. Osteoporos Int (2007) 0.80
Patients with hip fracture: what can be improved? Bone (2006) 0.79
Bisphosphonates and the upper gastrointestinal tract: skeletal gain without visceral pain? Mayo Clin Proc (2002) 0.77
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Trends in hip fracture rates in Canada. JAMA (2009) 2.95
Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem (2009) 1.85
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
A before-and-after study of fracture risk reporting and osteoporosis treatment initiation. Ann Intern Med (2010) 1.51
Use of nonsteroidal antiinflammatory drugs: is there a change in patient risk profile after withdrawal of rofecoxib? J Rheumatol (2010) 1.39
Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res (2007) 1.28
Osteoporosis-related fracture case definitions for population-based administrative data. BMC Public Health (2012) 1.11
Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J (2011) 1.11
Dietary patterns and incident low-trauma fractures in postmenopausal women and men aged ≥ 50 y: a population-based cohort study. Am J Clin Nutr (2010) 1.06
Independent external validation of nomograms for predicting risk of low-trauma fracture and hip fracture. CMAJ (2010) 0.92
Abdominal fat from spine dual-energy x-ray absorptiometry and risk for subsequent diabetes. J Clin Endocrinol Metab (2010) 0.91
Trends in hip fracture rates in Canada: an age-period-cohort analysis. J Bone Miner Res (2013) 0.84
The burden of illness of osteoporosis in Canadian men. J Bone Miner Res (2012) 0.82
An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures. J Bone Miner Res (2013) 0.82
Fracture burden in relation to low bone mineral density and FRAX(®) probability. J Clin Densitom (2011) 0.81
Prevalence of vitamin D insufficiency and associated factors among Canadian Cree: a cross-sectional study. Can J Public Health (2013) 0.80
Direct medical resource utilization associated with osteoporosis-related nonvertebral fractures in postmenopausal women. J Bone Miner Res (2013) 0.80
Conjugated linoleic acid is related to bone mineral density but does not affect parathyroid hormone in men. Nutr Res (2012) 0.77
Determining whether women with osteopenic bone mineral density have low, moderate, or high clinical fracture risk. Menopause (2010) 0.77
Concordance with guideline recommendations: previous and more recent nonsteroidal anti-inflammatory drug prescriptions in Quebec, Canada. Pharmacoepidemiol Drug Saf (2012) 0.76
The thinker's sign. CMAJ (2008) 0.75
Persistent headache after earache. CMAJ (2010) 0.75
Isoflavones and bone health. Menopause (2004) 0.75
Discrepancy among observational studies: example of naproxen-associated adverse events. Open Rheumatol J (2009) 0.75
Forearm bone mineral density varies as a function of adiposity in inuit women 40-90 years of age during the vitamin D-synthesizing period. Calcif Tissue Int (2012) 0.75